Breast cancer cases (n = 48) |
Healthy controls (n = 48) | |
---|---|---|
Age (years) | ||
Mean (± SD) | 58 (± 14) | 53 (± 9) |
Menopause status, n (%) | ||
Pre | 16 (33) | - |
Post | 30 (63) | - |
Missing | 2 (4) | 48 (100) |
Sample storage duration (months) | ||
Median (IQR) | 16 (11–35) | 17 (11–31) |
Time from diagnosis to blood sampling (days) | ||
Median (IQR) | 7 (0–20) | |
Stage, n (%) | ||
IIA | 26 (54) | |
IIB | 11 (23) | |
IIIA | 6 (13) | |
IIIC | 5 (10) | |
Tumor size, n (%) | ||
> 0.5 – 1 cm | 2 (4) | |
> 1 – 2 cm | 16 (33) | |
> 2 – 5 cm | 28 (58) | |
> 5 cm | 2 (4) | |
Lymph node involvement, n (%) | ||
No | 9 (19) | |
1–3 | 29 (60) | |
> 3 | 10 (21) | |
Differentiation, n (%) | ||
High | 6 (13) | |
Intermediate | 19 (40) | |
Low | 22 (46) | |
Unknown | 1 (2) | |
ER status, n (%) | ||
Negative | 13 (27) | |
Positive | 35 (73) | |
PR status, n (%) | ||
Negative | 20 (42) | |
Positive | 28 (58) | |
Her2/neu expression, n (%) | ||
Negative | 36 (75) | |
Positive | 12 (25) | |
P53 expression, n (%) | ||
Negative | 18 (38) | |
Positive | 24 (50) | |
Missing | 6 (13) |